Literature DB >> 34311842

Revisiting the guidelines for ending isolation for COVID-19 patients.

Yong Dam Jeong1,2, Keisuke Ejima3, Kwang Su Kim1, Shoya Iwanami1, Ana I Bento3, Yasuhisa Fujita1, Il Hyo Jung2, Kazuyuki Aihara4, Koichi Watashi5,6,7, Taiga Miyazaki8,9, Takaji Wakita5, Shingo Iwami1,10,11,12,13, Marco Ajelli3,14.   

Abstract

Since the start of the COVID-19 pandemic, two mainstream guidelines for defining when to end the isolation of SARS-CoV-2-infected individuals have been in use: the one-size-fits-all approach (i.e. patients are isolated for a fixed number of days) and the personalized approach (i.e. based on repeated testing of isolated patients). We use a mathematical framework to model within-host viral dynamics and test different criteria for ending isolation. By considering a fixed time of 10 days since symptom onset as the criterion for ending isolation, we estimated that the risk of releasing an individual who is still infectious is low (0-6.6%). However, this policy entails lengthy unnecessary isolations (4.8-8.3 days). In contrast, by using a personalized strategy, similar low risks can be reached with shorter prolonged isolations. The obtained findings provide a scientific rationale for policies on ending the isolation of SARS-CoV-2-infected individuals.
© 2021, Jeong et al.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; human; infectious disease; isolation; mathematical model; microbiology; personalized medicine

Mesh:

Year:  2021        PMID: 34311842      PMCID: PMC8315804          DOI: 10.7554/eLife.69340

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  37 in total

1.  Efficient Pharmacokinetic Modeling Workflow With the MonolixSuite: A Case Study of Remifentanil.

Authors:  Pauline Traynard; Géraldine Ayral; Monika Twarogowska; Jonathan Chauvin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-03-31

2.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.

Authors:  Barnaby Edward Young; Sean Wei Xiang Ong; Shirin Kalimuddin; Jenny G Low; Seow Yen Tan; Jiashen Loh; Oon-Tek Ng; Kalisvar Marimuthu; Li Wei Ang; Tze Minn Mak; Sok Kiang Lau; Danielle E Anderson; Kian Sing Chan; Thean Yen Tan; Tong Yong Ng; Lin Cui; Zubaidah Said; Lalitha Kurupatham; Mark I-Cheng Chen; Monica Chan; Shawn Vasoo; Lin-Fa Wang; Boon Huan Tan; Raymond Tzer Pin Lin; Vernon Jian Ming Lee; Yee-Sin Leo; David Chien Lye
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

3.  Kinetics of influenza A virus infection in humans.

Authors:  Prasith Baccam; Catherine Beauchemin; Catherine A Macken; Frederick G Hayden; Alan S Perelson
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

4.  Quantifying the effect of Vpu on the promotion of HIV-1 replication in the humanized mouse model.

Authors:  Hiroki Ikeda; Shinji Nakaoka; Rob J de Boer; Satoru Morita; Naoko Misawa; Yoshio Koyanagi; Kazuyuki Aihara; Kei Sato; Shingo Iwami
Journal:  Retrovirology       Date:  2016-04-18       Impact factor: 4.602

5.  Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing.

Authors:  Yuan-Po Tu; Rachel Jennings; Brian Hart; Gerard A Cangelosi; Rachel C Wood; Kevin Wehber; Prateek Verma; Deneen Vojta; Ethan M Berke
Journal:  N Engl J Med       Date:  2020-06-03       Impact factor: 91.245

6.  Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2.

Authors:  Wei Wang; Lidong Gao; Cécile Viboud; Hongjie Yu; Kaiyuan Sun; Yan Wang; Kaiwei Luo; Lingshuang Ren; Zhifei Zhan; Xinghui Chen; Shanlu Zhao; Yiwei Huang; Qianlai Sun; Ziyan Liu; Maria Litvinova; Alessandro Vespignani; Marco Ajelli
Journal:  Science       Date:  2020-11-24       Impact factor: 47.728

7.  Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).

Authors:  Jeroen J A van Kampen; David A M C van de Vijver; Pieter L A Fraaij; Bart L Haagmans; Mart M Lamers; Nisreen Okba; Johannes P C van den Akker; Henrik Endeman; Diederik A M P J Gommers; Jan J Cornelissen; Rogier A S Hoek; Menno M van der Eerden; Dennis A Hesselink; Herold J Metselaar; Annelies Verbon; Jurriaan E M de Steenwinkel; Georgina I Aron; Eric C M van Gorp; Sander van Boheemen; Jolanda C Voermans; Charles A B Boucher; Richard Molenkamp; Marion P G Koopmans; Corine Geurtsvankessel; Annemiek A van der Eijk
Journal:  Nat Commun       Date:  2021-01-11       Impact factor: 14.919

8.  Saliva TwoStep for rapid detection of asymptomatic SARS-CoV-2 carriers.

Authors:  Qing Yang; Nicholas R Meyerson; Stephen K Clark; Camille L Paige; Will T Fattor; Alison R Gilchrist; Arturo Barbachano-Guerrero; Benjamin G Healy; Emma R Worden-Sapper; Sharon S Wu; Denise Muhlrad; Carolyn J Decker; Tassa K Saldi; Erika Lasda; Patrick Gonzales; Morgan R Fink; Kimngan L Tat; Cole R Hager; Jack C Davis; Christopher D Ozeroff; Gloria R Brisson; Matthew B McQueen; Leslie A Leinwand; Roy Parker; Sara L Sawyer
Journal:  Elife       Date:  2021-03-29       Impact factor: 8.140

9.  Saliva is a reliable tool to detect SARS-CoV-2.

Authors:  Lorenzo Azzi; Giulio Carcano; Francesco Gianfagna; Paolo Grossi; Daniela Dalla Gasperina; Angelo Genoni; Mauro Fasano; Fausto Sessa; Lucia Tettamanti; Francesco Carinci; Vittorio Maurino; Agostino Rossi; Angelo Tagliabue; Andreina Baj
Journal:  J Infect       Date:  2020-04-14       Impact factor: 6.072

10.  Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events.

Authors:  Ashish Goyal; Daniel B Reeves; E Fabian Cardozo-Ojeda; Joshua T Schiffer; Bryan T Mayer
Journal:  Elife       Date:  2021-02-23       Impact factor: 8.713

View more
  5 in total

1.  Prolonged viral shedding in severely ill patients infected with SARS-CoV-2 Delta variants: A retrospective cohort study.

Authors:  Yae Jee Baek; Youn-Jung Lee; Jae In Kim; Seju Lee; Jinnam Kim; Eun Hwa Lee; Ki Hyun Lee; Jung Ho Kim; Jin Young Ahn; Su Jin Jeong; Nam Su Ku; Joon-Sup Yeom; Jun Yong Choi
Journal:  J Infect       Date:  2022-04-05       Impact factor: 38.637

2.  Model-based evaluation of alternative reactive class closure strategies against COVID-19.

Authors:  Quan-Hui Liu; Juanjuan Zhang; Cheng Peng; Maria Litvinova; Shudong Huang; Piero Poletti; Filippo Trentini; Giorgio Guzzetta; Valentina Marziano; Tao Zhou; Cecile Viboud; Ana I Bento; Jiancheng Lv; Alessandro Vespignani; Stefano Merler; Hongjie Yu; Marco Ajelli
Journal:  Nat Commun       Date:  2022-01-14       Impact factor: 14.919

3.  Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.

Authors:  Yuan Bai; Mingwang Shen; Lei Zhang
Journal:  Viruses       Date:  2022-04-06       Impact factor: 5.818

4.  Designing isolation guidelines for COVID-19 patients with rapid antigen tests.

Authors:  Yong Dam Jeong; Keisuke Ejima; Kwang Su Kim; Woo Joohyeon; Shoya Iwanami; Yasuhisa Fujita; Il Hyo Jung; Kazuyuki Aihara; Kenji Shibuya; Shingo Iwami; Ana I Bento; Marco Ajelli
Journal:  Nat Commun       Date:  2022-08-20       Impact factor: 17.694

5.  Designing isolation guidelines for COVID-19 patients utilizing rapid antigen tests: a simulation study using viral dynamics models.

Authors:  Yong Dam Jeong; Keisuke Ejima; Kwang Su Kim; Woo Joohyeon; Shoya Iwanami; Yasuhisa Fujita; Il Hyo Jung; Kenji Shibuya; Shingo Iwami; Ana I Bento; Marco Ajelli
Journal:  medRxiv       Date:  2022-01-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.